Diversify Wealth Management LLC Invests $1.12 Million in Novartis AG $NVS

Diversify Wealth Management LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,856 shares of the company’s stock, valued at approximately $1,123,000.

Several other institutional investors have also added to or reduced their stakes in NVS. Arlington Trust Co LLC purchased a new stake in Novartis in the fourth quarter worth $25,000. CrossGen Wealth LLC bought a new position in shares of Novartis in the fourth quarter worth about $28,000. Bank of Jackson Hole Trust grew its holdings in shares of Novartis by 425.0% in the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 187 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in Novartis in the 3rd quarter worth about $33,000. Finally, Nalls Sherbakoff Group LLC bought a new stake in Novartis during the 4th quarter valued at about $34,000. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein raised shares of Novartis to a “hold” rating in a research report on Thursday, March 19th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley increased their price objective on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Novartis has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Trading Up 0.4%

NYSE NVS opened at $150.89 on Thursday. Novartis AG has a one year low of $112.34 and a one year high of $170.46. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The company has a market capitalization of $287.93 billion, a price-to-earnings ratio of 21.62, a price-to-earnings-growth ratio of 2.59 and a beta of 0.45. The company’s 50-day simple moving average is $151.11 and its two-hundred day simple moving average is $151.49.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business had revenue of $13.52 billion during the quarter, compared to analysts’ expectations of $13.44 billion. During the same period in the previous year, the company posted $2.28 EPS. Novartis’s revenue for the quarter was down .9% on a year-over-year basis. Equities analysts forecast that Novartis AG will post 8.77 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.